The record / Two analogs compared
Sermorelin vs CJC-1295: GHRH Analogs Compared in Research
The short-acting native fragment beside its long-acting engineered cousin — what differs, what stays the same, and why the half-life is the whole story.
The short version
Sermorelin vs CJC-1295 is really a story about how long a molecule lasts. Both are GHRH analogs — both tell the pituitary to make growth hormone through the same receptor. The difference is durability: native sermorelin clears the blood in about 10-12 minutes, while CJC-1295 adds a chemical group (DAC) that grabs onto a blood protein (albumin) so it lasts far longer. Sermorelin's very short life is exactly what motivated engineers to build longer-acting cousins like CJC-1295. This page compares the two by design and half-life; it recommends neither.
How does sermorelin compare to CJC-1295?
Both sermorelin and CJC-1295 are GHRH analogs that act on the same GHRH receptor to stimulate the body's own GH [3][4]. The headline difference is duration. Native sermorelin — GHRH(1-29) — has a very short plasma half-life, on the order of 10-12 minutes [3]. CJC-1295 adds a Drug Affinity Complex (DAC): a chemical group that binds serum albumin and dramatically extends the analog's time in circulation. CJC-1295 is, in effect, the durability-engineered descendant of the same 1-29 sequence sermorelin is built from.
Sermorelin half-life: the reason longer-acting analogs exist
Sermorelin half-life is the hinge of this comparison. After intravenous dosing, GHRH(1-29) is cleared from plasma in roughly 10-12 minutes [3]. That single fact — a molecule that does its job and then vanishes within minutes — is exactly what motivated medicinal chemists to stabilize the fragment.
Two design moves followed. The first was point substitution: replacing residues prone to enzymatic clipping (the D-Ala2 substitution is the classic example) to slow degradation. The second, and more dramatic, was the DAC technology behind CJC-1295 — attaching a maleimide group that binds circulating albumin, so the analog is carried for far longer than minutes.
The trade is real and worth naming plainly. Native sermorelin preserves a brief, sharp, naturally pulsatile GH stimulus that rides the body's own rhythm [4]; a long-acting analog raises the integrated GH/IGF-1 signal over a much longer window. Neither is presented here as preferable — the comparison is mechanical, not a recommendation.
How does sermorelin compare to CJC-1295? (at the design level)
At the molecular level the two analogs share the active GHRH(1-29) core but diverge on stabilization. Sermorelin is the bare native fragment: full GHRH activity [3], short plasma residence [3], a sharp pulsatile stimulus, and physiologic feedback fully intact [4]. CJC-1295 keeps the GHRH-receptor mechanism but adds the DAC albumin-binding group to extend action far beyond sermorelin's minutes. One is the physiologic short pulse; the other is the engineered long signal. The right way to read the pair is as a half-life spectrum built on a shared mechanism, not as two unrelated drugs.
How does sermorelin differ from direct HGH injections?
Sermorelin acts upstream on the pituitary to stimulate the body's own pulsatile GH, so somatostatin and IGF-1 feedback stay intact [4]. Injected recombinant GH supplies the hormone directly and bypasses that regulation. An editorial argued the secretagogue approach may be more physiologic for adult GH insufficiency precisely because it preserves the natural feedback and pulse [4] — a structural difference, reported, not endorsed.
Why the comparison matters for reading the literature
Keeping sermorelin and CJC-1295 distinct prevents a common error: importing data from one onto the other. Body-composition and cognition findings in the modern literature often come from stabilized, long-acting GHRH analogs — tesamorelin most clearly [6] — whose extended exposure profile is unlike native sermorelin's brief pulse. A result obtained with a long-acting analog cannot be assumed to hold for the short-acting native fragment, and vice versa.
That is why this digest labels which analog produced which finding. The shared GHRH-receptor mechanism makes the family coherent; the divergent half-lives make the individual evidence non-interchangeable. Read the analog, not just the class. The full source list is on the sermorelin references and citations page.